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Summary: The following 6 commercially available 125I-labelled digoxin radioimmunoassay kits were tested:
A. Clinical Assays Gammacoat 125I Digoxin Radioimmunoassay Kit.
B. Abbott Digoxin 1125 Imusay Kit.
C. Schwarz-Mann Digoxin AbTRAC (125I) Radioimmunoassay Kit.
D. Squibb Digoxin Immutope Kit.
E. Boehringer-Mannheim Digoxin Radioimmunoassay Kit.
F. Corning Immophase Digoxin Radioimmunoassay Kit.
The Clinical Assays kit was used as the "reference" kit against which the other 5 kits were compared, as this kit
had been in routine use for 15 months. These kits showed good correlation with the reference kit (p < 0.001). Kits
-D were tested to see if the high circulating steroids in the second half of a clinically normal pregnancy influenced
kit performance. In these kits no "digoxin" level above 0.38 nmol · liter"1 was recorded, despite the high cortisol
(712-1584 nmol · liter'1) and total oestriol (69-800 nmol - liter"1) levels in serum.
When serum from 49 hospitalised patients not under digoxin therapy were measured with the same 4 kits, one kit
gave 5 false positive results (0.52-0.90 nmol · liter"1), whereas the other 3 gave results below 0.52 nmol - liter"1.
In another 49 hospitalised patients undergoing regular digoxin therapy, the greatest discrepancy between these 4
kits in measuring digoxin in a single serum was 1.15 nmol · liter"1.
In the kits employing antibody-coated tubes, modification of procedure often led to improved sensitivity and
therefore to better precision in the lower concentration range.
Untersuchungen von sechs kommerziellen I2sj-markierten Digoxin-Kits
Zusammenfassung: Es wurden folgende kommerziell erhältlichen 125J-Digoxin-Radioimmunoassay-Kits auf ihre
Vergleichbarkeit untersucht:
A. Clinical Assays Gammacoat 125I Digoxin Radioimmunoassay Kit.
B. Abbott Digoxin 1125 Imusay Kit.
C. Schwarz-Mann Digoxin AbTRAC (125I) Radioimmunoassay Kit.
D. Squibb Digoxin Immutope Kit,
E. Boehringer-Mannheim Digoxin Radioimmunoassay Kit.
F. Corning Immöphase Digoxin Radioimmunoassay Kit.
Der Clinical Assays Kit diente als „Referenz"-Kit, da dieser bei uns bereits 15 Monate lang in der Routine ange-
wandt würde und damit die größten Erfahrungen vorlagen.
Die Korrelationen der Ergebnisse der 5 Kits war gut, (p < 0.001). Die Kits A—D zeigten keine klinisch bedeutungs-
volle Kreüzreaktion („Digpxin'^Spiegel < 0.38 ilmol · liter"1) mit hohen Konzentrationen von Cortisol (712-1584
nmol - liter"1) und Gesamt-Oestriol (69^-800 nmol - liter"1) wie sie iii der 2. Schwangerschaftshälfte im Serum vor-
kommen,
Im Gegensatz dazu zeigte ein Kit 5 falsch-positive Werte (0.52-0.90 nmol · liter"1) in Seren von 49 Patienten ohne
Digöxinbehandlung. Die übrigen 3 Kits erbrachten Ergebnisse unter 0.52 nmol · liter"1. Bei weiteren 49 Patienten
unter Digöxinbehandlung wurden mit diesen 4 Kits z.T. erheblich unterschiedliche Werte gemessen. Die größte
Differenz betrug 1.15 nmol · liter"1.
Durch Modifikation der Kit-Vorschriften konnte die Empfindlichkeit, und damit die Präzision im unteren Meß-
bereich, der drei Coated-Tube-Assäys verbessert werden.
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Introduction
With the rapidly expanding use of commercial test kits,
a study was undertaken to compare six digoxin radio-
immunoassay kits, all using a 125Habelled digoxin
derivative as tracer. The kits were tested for quality and
reproducibility.
Four kits using differing techniques were further tested
for interfering substances in the following three clinical
situations:
a) In the second half of a clinically normal pregnancy
where circulating steroids are raised.
b) In hospital patients not undergoing digitalis therapy,
but receiving normal pharmaceutical preparations.
c) In hospital patients receiving regular digoxin therapy.
Finally, the three kits using the coated tube technique
were tested and modified to improve sensitivity and
reproducibility in the range under 1.28 nmol liter"1
digoxin.
Materials and Methods
The kits tested were from the following manufacturers:
A. Clinical Assays Gammacoat 125I Digoxin Radioimmunoassay
Kit (Clinical Assays, 217, Binney St., Massachusetts, USA).
B. Abbott Digoxin 1125 Imusay Kit (Abbott Laboratories,
North Chicago, Illinois, USA).
C. Schwarz4iann Digoxin Ab-TRAC (125I) Radioimmunoassay
Kit. (Schwarz-Mann, Orangeburg, New York, USA).
D. Squibb Digoxin Immutope Kit (£. R. Squibb and Sons inc.,
Princeton, New Jersey, USA).
E. Boehringer-Manriheim Digoxin Radioimmunoassay Kit
(Boehringer-Mannheim GmbH Diagnostika, D-8132 Tutzing
FRG).
F. Corning Immo Phase Digoxin Gamma Kit (I. M. A. GmbH,
D-6300 Gie en, FRG).
Tables 1 and 2 show the contents of each kit and the assay
procedure as given by the manufacturer.
In order to help assess sensitivity of each kit, an additional
standard of 0.26 nmol · liter"1 was made up from digoxin
(Boehringer-Mannheim) in digox vfree pool serum.
Serum cortisol was assayed with the Clinical Assays Gammacoat
125I Cortisol Radioimmunoassay Kit using the protocol issued.












































































































































*A - Antibody-coated tubes *B - Antibody-coated glass beads *C - Tracer lyophilised in antibody-coated tubes.
*D - Tracer combined with buffer *E -=· Buffer + coated beads already in tubes *F -^ 15 min pre-incubation at room temperature
before tracer addition and 37 °C main incubation *RT - Room Temperature
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The range covered by this kit was 0-1658 nmol · liter'1 using the
serum standards provided.
Serum total oestriol was measured using the Amersham Oestriol
125I Radioimmunoassay Kit, again using the protocol provided.
Serum samples were first hydrplysed with an enzyme pre-
paration (a mixture of 0-glucuronidase and aryl sulphatase)
provided in the kit. Separation of bound and free oestriol was
with ammonium sulphate and the range covered by the kit was
0-1190 nmol -liter"1.
Blood was taken from women attending the gynaecological
outpatient clinic and who were in the second half of a clinically
normal pregnancy. Blood for the other investigations was
obtained from samples sent for routine analysis. In all cases,
blood was taken by venesection between 07.00 and 10.00 hr.
The serum from all samples was äliquotted and frozen at - 20° C
until assay. All assays in the same experiment (e.g. pregnancy
series) were carried out on the same day.
All standard curves were calculated using spline function with a
Siemens 404/3 Computer system. Sensitivity was defined as the
value on the standard curve corresponding to 3 standard
deviations from the zero standard (%B0) and also in nmol · liter"1.
In the assays employing antibody coated tubes modifications to
the assays were made to improve sensitivity and reproducibility.
Kinetic studies were carried out with one kit in order to develop
an emergency assay for digoxin, giving results inside one hour
from receipt of heparinised blood.
Results
Kit performance
Each kit was tested with the protocol sent by the
manufacturer and the sensitivity, 50% intercept and
intra-assay variation determined. In the case of the kits
from Abbott, Boehringer^Mannheim and Schwarz-Mann,
there were changes either in the protocol or production
method and results from kits employing the changed
method reported (tab. 3).
Table 4 shows the modifications made to the three
coated tube assays and their effect on sensitivity and
reproducibility. Each manufacturer was allotted two
pool-sera, one with low- and one with high digoxin
levels. The sera were so collected that the values were
similar in each of the low-range and each of the high-
range pools.
Tables 3 and 4 show that a pre-incubation step at low
digoxin concentrations increases precision and often
reduces the value of the 50% intercept. At higher digoxin
concentrations, pre-incubation has little or no effect
on precision.
Development of an emergency assay (Clinical
Assays kit)
The aim here was to develop a quick and reliable
method for measuring digoxin concentrations in patients
who were either unconscious through an unknown drug
overdose, or in whom the question of overdigitalisation
arose.
Figure 1 shows the kinetics under three different
conditions on the maximum binding of tracer in the
presence of a digoxin-free serum. All three assays were
pre-incubated for 7 minutes at the same temperature as
the main incubation, before tracer was added to the
tubes.
The final form of the emergency assay was as follows:
Blood was taken into heparinised tubes and sent to the labor-
atory as quickly as possible where it was centrifuged and the
plasma removed for assay.
Standards were set up in singlicate to cover the range 0—10.24
nmol liter"1. Two quality control sera were also set up in
singlicate and the patient plasma in duplicate.
Tab. 3. Sensitivity and precision of kits using the protocol given.
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A. No pre-incubation at room temperature before tracer addition.
B. As per protocol, but with automatic pipette.
C. Emergency method.
D. Buffer addition before serum (In protocol is the opposite).
E. Boehringer coated tubes and standards, Clinical Assays buffer and tracer Clinical Assays protocol with pre-incubation.








Ο 10 20 30 (.0 50 60
Incubation [min]
Fig. 1. Kinetic studies on the maximum binding of a zero
standard at differing temperatures and tracer volumes.
ο ο 100 μΐ tracer, 37 °C.
Δ Δ 100 μΐ tracer, 45 °C.
ο ο 200 μ! tracer, 40 °C.
The abscissa represents the time in minutes from tracer
addition after 7 minutes pre-incubation at the assay
temperature shown in each case. The ordinate represents
counts per minute bound.
1 ml Tris buffer (0.01 mol/1, pH 7.4), provided in the kit, was
added to all tubes, followed by 50 μ! standard/serum/plasma.
The tubes were quickly vortexed and incubated for 7 minutes
at 40°C, 200 μΐ tracer added from a repeating syringe (Hamilton
PB-600 with 10 ml syringe) and the tubes incubated with
shaking for a further 20 minutes at 40 °C. The contents of the
tubes were then aspirated off and the tubes washed with 2 ml
Tris buffer, the contents again aspirated and the tube counted
for 1 minute in a gamma counter. The standard curve was
plotted by hand on semi-log paper provided with the kit and
the values read off for control sera and patient plasma as soon
as they were counted. If the quality control sera were within the
accepted limits (inside the 2 SD range) the results of the patient
sera were telephoned to the ward or doctor concerned.
The average time taken between receipt of blood and results was
between 45 and 55 minutes.
The Clinical Assays kit was chosen s it was the most
adaptable to such modification. Neither of the other
coated tube assay systems could be used, the Boehringer
kit offering no possibilities for pre-incubation, and the
Schwarz-Mann kit having tracer already in the tubes.
Tests for interfering compounds
The Clinical Assays, Abbott, Schwarz-Mann and Squibb
kits were tested in three differing clinical situations for
possible interfering substances.
The first group of patients were 39 women in the second
half of a clinically normal pregnancy. The kits were tested
to see if the high steroid levels in the maternal blood
affected the values obtained. All values should theoretic-
ally have been zero and in all four kits no false value
above 0.38 nmol · liter""1 was found. The cortisol levels *
in the women ranged from 712-1584 nmol - liter*1 and
were above those expected in non-pregnant women (1-3).
Serum total oestriol ranged from 69-800 nmol · liter"1
and correlated with the week of pregnancy as expected.
The second group under study were 49 patients in
hospital, not undergoing digoxin therapy, but receiving
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pharmaceutical preparations. No serum was excluded
from this group with the aim of including all possible
interference from icteric and fatty sera as well as those
with abnormal protein content. Here three kits gave no
result above 0.51 nmol · liter"1, but the Abbott kit
showed four false positive values between 0.51 and
0.90 nmol · liter"1. Serum cortisol levels in this group
were significantly lower than in the pregnant women
(range 36-1280 nmol · liter"1, ρ = 0.075). Serum
total oestriol was less than 25 nmol · liter"1 in
48 patients, the remaining value of 49 nmol · liter"1
occuring in a serum with low total protein, and in which
the Abbott kit also gave a reading of 0.51 nmol · liter"1.
Both kits used a separation method which is sensitive to
the globulin content of serum. The third group of 49
patients were receiving regular digoxin therapy and
were used to compare performance of these four kits. In
only one case did all four kits give the same result, in 29
cases two kits gave the same result, in 8 cases three kits
the same and in 11 cases all kits gave different results. In
16 cases the difference between the highest and lowest
values obtained for one serum was more than 0.5 nmol
• liter"1 (the largest difference was 1.15 nmol · liter"1).
Correlation between kits can be seen in table 5, using
the Clinical Assays kit as the reference kit.
This group showed similar serum cortisol levels to the
second group, (range 50-1208 nmol · liter"1). Four
patients showed serum total oestriol above 25 nmol
• liter"1, which corresponded with high digoxin levels
from the Abbott kit and which had low total protein
levels.
The correlations in Table 5 from the remaining three
kits were from separate studies using routine sera for
digoxin estimation. The Clinical Assays kit was used
as the reference method and was run at the same time
as the test kit.
The results from the Abbott kit were significantly
higher than those from the Schwarz-Mann kit (Wil-
coxon Rank Test U = 1004; ρ = 0.10).
Table 6 shows the results from each kit on the day
tested, using both commercial and laboratory quality
control sera. The same batches of control sera were
used throughout the study. The values for the control
sera lay in most cases within the ascribed limits,
except in the Byk-Mallinkrodt sera where the values
were repeatedly lower than those given. The differ-
ence in values given for the different control sera are
greater in the lower range than in the higher one. Inter-
assay control was only carried out for the Clinical
Assays kit using the laboratory precision sera (Table 6)
when, over a 4 month period, the coefficient of
variation at the lower level was 12.6%, and at the
higher level was 11.4%. These values were obtained
from 60 assays performed by the same technician.
In the other kits an inter-assay precision study was
ruled out due to cost.
Tab. 5. Correlation between the 6 kits tested. All are compared
with the Clinical Assays kit as reference.





























* Regression constants for the equation y = a + bx















































































*Mean value from 8 kits tested by manufacturer. +Value given for kit A **Value given for kit C
++lnter-assay values given by Clinical Assays kit over 4 months.
Kit A ̂  Clinical Assays. Kit B ̂  Abbott, Kit C - Schwarz^Mann. Kit D - Squibb. Kit E - Boehringer-Mannheim.
Kit F - Corning.
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Tab. 7. Measured amounts of digoxin in 5 kit standards, using





























































Kit B - Abbott
Kit C - Schwarz-Mann
Kit D - Squibb
Kit E - Boehringer-Mannheim
Kit F - Corning .
Finally as a comparison of quality of the standards, all
standards were measured in the Clinical Assays kit and
the results tabulated (tab. 7). The results show good
agreement in all kit standards.
Discussion
The need to determine serum digoxin levels was em-
phasised before the introduction of a radioimmunoassay
by Smith et al. (4). Since then, the pharmacokinetics
and bioavailability of different preparations has been
adequately described, (5-11). The need for a kit which
is precise and accurate throughout the whole range of
digoxin levels found in the blood has been highlighted
by several authors (12-15), who have described the
differing response to digoxin in different clinical
situations, where toxic symptoms may occur at very
much lower concentrations than those normally en-
countered.
As in many radioimmunoassays, reports of substances
causing interference have been reported for digoxin.
These include digoxin analogues (16), the effect of
serum proteins (17-18), and the separation technique
(19), all of which can give rise to false digoxin levels
(20-23). Judging from some results, this problem has
still not been solved (24-25), though with the intro-
duction of 125I-labelling, many problems arising from
beta-scintillation counting such as quench-effects have
disappeared (26-27). The correlation between kits
using 3H and 125I labelling is as good as between the
six 125Habelled kits tested here (26-27).
In the Federal Republic of Germany (FRG), due to the
decentralised nature of health care, (as in contrast to the
British National Health Service, for example,) many
digoxin estimations are carried out in private laboratories
or small hospitals. As many of these have no facilities for
the raising and testing of antisera, or for the labelling of
antigens, the use of commercial kits has increased
enormously. Many of these kits are imported, only a
few being produced in the FRG. In the comparison of
commercial kits by other authors in different clinical
situations, such as acute renal failure (16), or cardiac
patients on diuretics and exercise (26), large discrep-
ancies were apparent in the results from different kits.
When results from this study and another from 1974
(27) are compared, it may be deduced that an im-
provement of kit components has occurred over the
past three years.
The use of12 5I-labelling has led to quicker and simpler
methods and this study has shown that while in many
cases the kits all deliver similar results, in other cases
there are still problems, which can be overcome by
relatively small changes in procedure. Oversimplific-
ation of kits can lead to unacceptably poor precision,
seen here in some of the antibody ̂ coated tube methods
at low digoxin concentration. The non-optimal method-
ology of kits for insulin and thyrotropin (TSH) has
been published elsewhere (28-29). It has been demon^
strated, that a pre-incubation to reduce non-specific
adsorption phenomena often increases reproducibility
at low serum levels of digoxin. In the Schwarz-Mann
kit, the simple reversal of addition of buffer and serum
led to marked improvement in precision at low levels.
The kit components are mostly very good as shown by
using the Boehringer-Mannheim coated tubes and
standards with preincubation and with the tracer,
buffer and protocol of Clinical Assays (Tables 3 and 4).
An example of the quality of the standards provided in
the kits is seen in Table 7. The results from the pregnant
women showed that the effect of high circulating
steroid levels had little or no effect on the kits, despite
the structural similarities with digoxin. In contrast, the
results from the hospitalised patients not taking digoxin
highlighted the probability of false results through
medication and serum proteins in some kits. It was
interesting to note that the two methods, namely the
Abbott digoxin and Amersham oestriol kits, which
used a protein-sensitive separation technique, gave false
positive results in the same serum samples. The addition
of carrier serum before separation in the Abbott kit, as
recommended in another kit using polyethylene glycol
separation (30), may very well abolish many false
positive results with this kit.
In conclusion it may be said that while the quality of kit
components is on average very good, major improvements
can be attained by minor modification in procedure.
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